Phase II Study of MLN8237 in Advanced / Metastatic Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Alisertib (Primary)
- Indications Sarcoma; Urogenital cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2016 Status changed from suspended to active, no longer recruiting.
- 13 Jul 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.